Analyst Ratings For Mersana Therapeutics (NASDAQ:MRSN)
Today, HC Wainwright initiated coverage on Mersana Therapeutics (NASDAQ:MRSN) with a Buy.
Some recent analyst ratings include
- 2/15/2018-HC Wainwright initiated coverage with a Buy rating.
- 7/24/2017-Wedbush Reiterated Rating of Outperform .
- 7/24/2017-Leerink Swann initiated coverage with a Outperform rating.
- 7/24/2017-JPMorgan Chase & Co. initiated coverage with a Overweight rating.
- 7/24/2017-Cowen initiated coverage with a Outperform rating.
- On 7/3/2017 M James Barrett, Major Shareholder, bought 1,000,000 with an average share price of $15.00 per share and the total transaction amounting to $15,000,000.00.
Recent Trading Activity for Mersana Therapeutics (NASDAQ:MRSN)
Shares of Mersana Therapeutics closed the previous trading session at 15.16 down -0.16 1.04% with 14.6899995803833 shares trading hands.